*dizziness<ref name = "Leach"/><ref name=RAMP>{{cite journal|last=Parkinson Study Group|title=A multicenter randomized controlled trial of remacemide hydrochloride as monotherapy for PD.|journal=Neurology|date=2000-04-25|volume=54|issue=8|pages=1583–8|pmid=10762497|doi=10.1212/wnl.54.8.1583}}</ref>

 
*nausea<ref name= RAMP/>

 


 
Unlike many other treatments for epilepsy, remacemide does not appear to impair cognitive performance<ref>{{cite journal|last=Lockton|first=JA|author2=Cole G |author3=Hammersley M |author4=Wesnes K |title=Cognitive function is unaffected by remacemide at therapeutic relevant single doses|journal=J Psychopharmacol|year=1998|volume=12|issue=A41}}</ref><ref>{{cite journal|last=Lockton|first=JA|author2=Wesnes KA |author3=Yeates N |author4=Rolan O |author5=Diggory G |title=Remacemide does not affect cognitive function following multiple dosing|journal=J Psychopharmacol|year=1998|volume=12|issue=A41}}</ref><ref>{{cite journal|last=Wesnes|first=K.A.|author2=Edgar, C. |author3=Dean, A.D.P. |author4=Wroe, S.J. |title=The cognitive and psychomotor effects of remacemide and carbamazepine in newly diagnosed epilepsy|journal=Epilepsy & Behavior|date=1 March 2009|volume=14|issue=3|pages=522–528|doi=10.1016/j.yebeh.2008.11.012|pmid=19111629}}</ref> or driving performance<ref>{{cite journal|first=J.|last=Ramaekers |author2=C. Lamers |author3=F. Verhey |author4=N. Muntjewerff |author5=E. Mobbs |author6=N. Sanders |author7=J. Lewis |author8=J. Lockton |title=A comparative study of the effects of carbamazepine and the NMDA receptor antagonist remacemide on road tracking and car-following performance in actual traffic|journal=Psychopharmacology|date=1 January 2002|volume=159|issue=2|pages=203–210|doi=10.1007/s002130100898 |pmid=11862350}}</ref> in humans, although the evidence for effects on cognitive performance in animals has been mixed.<ref>{{cite journal|last1=Wright|first1=LK|last2=Pearson|first2=EC|last3=Hammond|first3=TG|last4=Paule|first4=MG|title=Behavioral effects associated with chronic ketamine or remacemide exposure in rats|journal=Neurotoxicol Teratol|date=May–Jun 2007|volume=29|issue=3|pages=348–59|doi=10.1016/j.ntt.2006.12.004|pmid=17291718}}</ref><ref>{{cite journal|last=Popke|first=E.J|author2=Allen, R.R |author3=Pearson, E.C |author4=Hammond, T.G |author5=Paule, M.G |title=Differential effects of two NMDA receptor antagonists on cognitive–behavioral development in nonhuman primates I|journal=Neurotoxicology and Teratology|date=1 July 2001|volume=23|issue=4|pages=319–332|doi=10.1016/S0892-0362(01)00156-8}}</ref><ref>{{cite journal|last=Popke|first=E.J|author2=Allen, R.R |author3=Pearson, E.C |author4=Hammond, T.G |author5=Paule, M.G |title=Differential effects of two NMDA receptor antagonists on cognitive–behavioral performance in young nonhuman primates II|journal=Neurotoxicology and Teratology|date=1 July 2001|volume=23|issue=4|pages=333–347|doi=10.1016/S0892-0362(01)00138-6}}</ref><ref>{{cite journal|last=Popke|first=E.J|author2=Patton, R |author3=Newport, G.D |author4=Rushing, L.G |author5=Fogle, C.M |author6=Allen, R.R |author7=Pearson, E.C |author8=Hammond, T.G |author9=Paule, M.G  |title=Assessing the potential toxicity of MK-801 and remacemide:|journal=Neurotoxicology and Teratology|date=1 March 2002|volume=24|issue=2|pages=193–207|doi=10.1016/S0892-0362(02)00206-4}}</ref><ref>{{cite journal|last=PAULE|first=MERLE G.|author2=FOGLE, C. MATTHEW |author3=ALLEN, RICHARD R. |author4=PEARSON, EDWIN C. |author5=HAMMOND, TIMOTHY G. |author6=POPKE, E. JON |title=Chronic Exposure to NMDA Receptor and Sodium Channel Blockers during Development in Monkeys and Rats|journal=Annals of the New York Academy of Sciences|date=1 May 2003|volume=993|issue=1|pages=116–122|doi=10.1111/j.1749-6632.2003.tb07519.x}}</ref> 

 
Remacemide is not a sedative.<ref name =preclinmice/>

 

